tradingkey.logo
搜尋

Caris Life Sciences Inc

CAI
添加自選
17.820USD
-0.500-2.73%
收盤 06/30, 16:00美東報價延遲15分鐘
5.04B總市值
虧損本益比TTM

Caris Life Sciences Inc

17.820
-0.500-2.73%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.73%

5天

+2.95%

1月

+6.58%

6月

-34.77%

今年開始到現在

-33.95%

1年

-33.53%

關鍵數據
18.300今開
18.585最高
3.76M成交量
虧損本益比TTM
48.57本益比動
--股利TTM
1.33%換手率
18.320昨收
17.500最低
54.58M成交額
虧損本益比靜
8.49市淨率
0.00%股息率 TTM
4.67%ROA
42.50052週最高
0.94量比
-378.26M淨利潤
282.65M總股本
-2.7620每股盈餘TTM
--Beta
--ROE
16.28052週最低
5.92%振幅
65.39%毛利率
5.04B總市值
2.97回報/風險
3.83%風險率

TradingKey Caris Life Sciences Inc股票評分

單位: USD 更新時間: 2026-06-29

操作建議

Caris Life Sciences Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值低估,在醫療設備與耗材行業排名78/204位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為28.33。中期看,股價處於平穩狀態。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Caris Life Sciences Inc評分

相關信息

行業排名
78 / 204
全市場排名
184 / 4570
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看好

Caris Life Sciences Inc亮點

亮點風險
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
業績高增長
公司營業收入穩步增長,連續3年增長165.26%
利潤高增長
公司淨利潤處於行業前列,最新年度總收入812.03M美元
估值低估
公司最新PE估值-6.63,處於3年歷史低位
史丹利·德魯肯米勒持倉
明星投資者史丹利·德魯肯米勒持倉,最新持倉2.20M股

分析師目標

基於 12 分析師
買入
評級
28.333
目標均價
+54.66%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Caris Life Sciences Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Caris Life Sciences Inc簡介

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
公司代碼CAI
公司Caris Life Sciences Inc
CEOHalbert (David Dean)
網址https://www.carislifesciences.com/

常見問題

Caris Life Sciences Inc(CAI)的當前股價是多少?

Caris Life Sciences Inc(CAI)的當前股價是 18.32。

Caris Life Sciences Inc 的股票代碼是什麼?

Caris Life Sciences Inc的股票代碼是CAI。

Caris Life Sciences Inc股票的52週最高點是多少?

Caris Life Sciences Inc股票的52週最高點是42.50。

Caris Life Sciences Inc股票的52週最低點是多少?

Caris Life Sciences Inc股票的52週最低點是16.28。

Caris Life Sciences Inc的市值是多少?

Caris Life Sciences Inc的市值是5.23B。

現在Caris Life Sciences Inc(CAI)的股票是買入、持有還是賣出?

根據分析師評級,Caris Life Sciences Inc(CAI)的總體評級為買入,目標價格為28.33。

Caris Life Sciences Inc(CAI)股票的每股收益(EPS TTM)是多少

Caris Life Sciences Inc(CAI)股票的每股收益(EPS TTM)是-3.22。
KeyAI